The ophthalmic medical company invested 464 million yuan in two industrial fund companies

【Pharmaceutical Network Enterprise News】On November 2, OPCOM Vision announced that OPCOM Vision Investment Co.
, Ltd.
, a wholly-owned subsidiary of the company, contributed RMB 115 million with its own funds to participate in the establishment of the fund Anhui Shanhong Venture Capital Partnership (Limited Partnership) (proposed name).

It is understood that the fund size of Anhui Shanhong Venture Capital Partnership (Limited Partnership) is 400 million yuan, which is paid
by all partners.
Among them, OPPLE Investment subscribed 115 million yuan, and the capital contribution ratio was 28.
75%.

It mainly invests in high-quality companies in innovative medical devices, biomedicine and medical services, focusing on medical device segments, focusing on investment projects
in ophthalmology and optometry, interventional devices and consumables, new biological materials, IVD fields, minimally invasive surgery and surgical robots.
On the same day, OPCOM Vision also issued an announcement that OPCOM Vision Investment Co.
, Ltd.
, a wholly-owned subsidiary of the company, will contribute RMB 349 million with its own funds to participate in the establishment of the fund Hefei Infineon Opple Health Technology Venture Capital Partnership (Limited Partnership).

The fund size of Hefei Infineon Health Technology Venture Capital Partnership (Limited Partnership) is 1 billion yuan, of which OPPLE Investment subscribed 349 million yuan, with a capital contribution ratio of 34.
90%.

The investment direction is mainly innovative materials, consumables, devices and other innovative technologies in the field of ophthalmology; It is supplemented by
new materials, high-value consumables, devices and other innovative technologies in fields other than ophthalmology.
It is reported that OPCOM Vision Technology Co.
, Ltd.
is a high-tech enterprise
focusing on eye health and myopia prevention and control technology and services.
The company's business includes ophthalmology and optometric medical devices (products) and medical services, and its current main products are rigid contact lenses (contact lenses) such as orthokeratology lenses and supporting care products
.
The industry believes that the future way out of China's economy lies in structural transformation and upgrading, which is mainly reflected in the domestic demand consumption industry with stable growth ability and continuous upgrading ability, and emerging industries with continuous innovation ability, so OPCOM Vision frequently invests in industrial fund companies and invests in high-quality enterprises and tracks
with real long-term competitiveness and growth.
In fact, in addition to OPCOM TV, many pharmaceutical companies are also investing in the establishment of private equity investment fund partnerships this year
.
For example, on June 6, Hengrui Pharmaceutical announced that in order to improve the company's capital operation ability and deepen the company's industrial layout, the company intends to sign the "Shanghai Shengdi Biopharmaceutical Private Equity Investment Fund Partnership (Limited Partnership) Partnership Agreement" with its holding subsidiary Shengdi Investment and Hengrui Group to jointly initiate the establishment of a partnership
.
Among them, the company and Hengrui Group, as limited partners (LP), each contributed 1 billion yuan, with a shareholding ratio of 49.
75%
respectively.
Anxu Biotech announced on June 2 that the company intends to use its own funds to initiate the establishment of Hangzhou Zhongchuan Anxu Equity Investment Partnership (Limited Partnership) with China Transmission Financial Holdings and Guohan Investment, mainly investing in enterprises/projects
in the fields of medicine, general health, and biomedicine in the entrepreneurial and growth stages.
The total capital contribution of the fund to be established this time shall not exceed 1 billion yuan
.
Among them, the company's subscribed capital contribution shall not exceed 500 million yuan, accounting for 50%
of the total capital contribution of the fund.
In addition, since the beginning of this year, Fosun Pharma has also issued four announcements
on participating in the establishment/subscription of private equity investment funds.
According to incomplete statistics, as of mid-June, more than 10 listed pharmaceutical companies in A-shares have entered private placement, and the investment field is concentrated in the medical and health track
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.